TransMedics Group, Inc.

TransMedics Group, Inc.

TMDX·NASDAQ

$69.69

+3.2%
HealthcareMedical - Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

At a Glance

Live Snapshot
Market Cap$2.41B
EPS5.6000
P/E Ratio12.44
Earnings Date07/29/2026

tmdx

Research Development Expenses

Last Annual Value

69.06M

3-Year CAGR

37%

5-Year CAGR

30%

10-Year CAGR

16%

TransMedics Group, Inc.

TransMedics Group, Inc. Competitors Analysis of research-development-expenses

TMDX · NASDAQ
Companyresearch-development-expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
69.06M
3.0%25.4%16.0% 
247.50M
20.4%24.8%N/A
150.61M
2.8%8.3%17.8%
395.20M
10.3%12.3%10.2%
368.14M
49.6%N/AN/A
316.60M
18.7%18.2%N/A
97.00M
-5.8%13.3%-1.2%
141.83M
-3.8%37.4%N/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
IMVT logo
Immunovant, Inc.
NASDAQ:IMVT
456.66M
41.8%46.1%N/A
TransMedics Group, Inc.

TransMedics Group, Inc. Fair Value Envelope

TMDX · NASDAQ

Our analysis suggests that TMDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $69.69, this represents a potential HIDDEN relative to our calculated worth for TransMedics Group, Inc..

Intrinsic Value
Current Price: $69.69